Dr. Min Li is Head of the Neurosciences Therapeutic Area Unit at GSK and oversees an R&D organization responsible for development from target discovery to clinical proof of concept (PoC). The NSTAU drug discovery programs are driven by foundational science, NSTAU focuses on discovering and developing medicines to treat diseases caused by hyper-excitatory responses and neurodegeneration, including Alzheimer’s and Parkinson’s diseases, and as well as pains and epilepsy.
Prior to joining GSK in 2014, Min spent nearly 20 years as a faculty member at Johns Hopkins University School of Medicine in Baltimore where he was a tenured Professor of Neuroscience and Physiology. In addition to directing well-funded independent research programs, he led NIH-funded national programs and several university-industry alliances that included long-term partnerships between Johns Hopkins and major companies.
Min is an author of more than 100 research papers, patents and books. His research reports have been published in journals including Science, Cell, and Nature. Awards and recognition for his research achievements include the Helen Hay Whitney Fellow, Sloan Neuroscience Fellow, Klingenstein Neuroscience Fellow, the NIH Shannon Investigator Award, Pfizer AHA fellow, and Established Investigator of AHA. He is also a Fellow of the American Association for the Advancement of Science.